Becton Dickinson (BDX) came out with quarterly earnings of $3.35 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.13%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.98 per share when it actually produced earnings of $3.43, delivering a surprise of 15.10%.Over the last four qua ...

Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Greg Rodetis - SVP, Treasurer & Head of Investor RelationsTom Polen - Chairman, CEO & PresidentChristopher DelOrefice - Executive VP & CFOMatthew Taylor - Managing DirectorTravis Steed - Managing Director - Equity ResearchMichael Feld - President & EVPDavid Roman - Managing Director Conference Call Participants Larry Biegelsen - AnalystRobbie Marcus - AnalystPatrick Wood - AnalystMatthew Miksic - Analyst ...

Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Hello, and welcome to Second Fiscal Quarter twenty twenty five Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com, or by phone at (800) 839-2385 for domestic calls and area code +1 402220203 for international calls. For today's call, all parties have been placed in a listen only mode until the question and answer se ...

Q2 FY25 Performance - Revenue reached $5.3 billion, with a 6.0% increase on a currency-neutral (FXN) basis, and a 0.9% increase organically[23] - Adjusted diluted EPS was $3.35, a 5.7% year-over-year increase[23] - Adjusted operating margin improved by 60 bps year-over-year to 24.9%[23] - Operating cash flow year-to-date was $0.9 billion[23] - Free cash flow year-to-date decreased by 44% to $623 million, reflecting planned one-time cash payments[35] Segment Performance - BD Medical revenue was $2.76 billion, up 14.3% FXN and 3.6% organically[23] - BD Life Sciences revenue was $1.247 billion, down 2.4% FXN (all organic)[23] - BD Interventional revenue was $1.264 billion, down 1.1% FXN (all organic)[23] FY25 Guidance - Estimated total company revenue is projected to be approximately $21.8 billion to $21.9 billion[37] - Adjusted revenue growth (FXN) is expected to be 7.8% to 8.3%[37] - Organic revenue growth (FXN) is projected to be 3.0% to 3.5%, which includes absorbing an approximate 175 bps impact from an expected decline in China, as well as Biosciences and Pharmaceutical Systems market dynamics[37] - Adjusted diluted EPS is guided to be $14.06 to $14.34, representing a 7.0% to 9.1% increase compared to $13.14 in FY24, inclusive of an estimated tariff impact of (25¢)[37]

Revenue Performance - Revenue for Q2 fiscal 2025 was $5.3 billion, representing a 4.5% increase as reported, 6.0% currency-neutral, and 0.9% organic growth[4] - Revenues for Q2 2025 were $5,272 million, representing a 4.5% increase compared to $5,045 million in Q2 2024[28] - For the first six months of fiscal year 2025, revenues reached $10,440 million, a 7.1% increase from $9,751 million in the same period of 2024[29] - Total revenues for the first quarter of fiscal year 2025 reached $5,272 million, a 4.5% increase compared to $5,045 million in the same period of 2024[38] - Total revenues for the six months ended March 31, 2025, were $10,440 million, representing a 7.1% increase compared to $9,751 million in the same period of 2024[47] - In the United States, total revenues increased by 7.0% to $3,108 million from $2,906 million year-over-year[32] - International revenues showed a slight increase of 1.2% to $2,164 million compared to $2,139 million in the previous year[35] Segment Performance - BD Medical segment revenue grew by 12.7% to $2.76 billion, driven by strong performance in Medication Management Solutions[8] - BD Life Sciences segment reported a revenue decline of 4.3% to $1.25 billion, impacted by lower demand in Diagnostic Solutions[8] - BD Medical segment reported total revenues of $2,760 million, up 12.7% from $2,449 million year-over-year[38] - BD Life Sciences segment total revenues decreased by 4.3% to $1,247 million from $1,304 million in the previous year[38] - BD Interventional segment revenues declined by 2.2% to $1,264 million compared to $1,292 million in the same quarter of 2024[38] - BD Medical organic revenue for the three months ended March 31, 2025, was $2,503 million, reflecting a 2.2% increase from $2,449 million in 2024[50] - BD Medical segment revenues increased to $5,375 million, a 14.9% increase from $4,679 million in 2024, with Medication Delivery Solutions growing by 3.8%[47] - BD Life Sciences segment reported revenues of $2,545 million, a decrease of 1.8% from $2,592 million in 2024, with Biosciences declining by 5.2%[47] Earnings and Guidance - GAAP diluted EPS was $1.07, down 42.2% from the previous year, while adjusted diluted EPS increased by 5.7% to $3.35[6] - Adjusted diluted EPS guidance for fiscal 2025 is now projected to be between $14.06 and $14.34, indicating a year-over-year growth of approximately 7.0% to 9.1%[16] - Reported diluted earnings per share (EPS) for the three months ended March 31, 2025, was $1.07, down 42.2% from $1.85 in 2024[53] - The company expects FY 2025 reported revenue growth to be between +8.0% to +8.5%, with total revenues projected to be approximately $21.8 to $21.9 billion[58] - Organic revenue growth for FY 2025 is anticipated to be between +3.0% to +3.5%[58] - The company anticipates a reported percentage change in earnings of +7.0% to +9.1% for FY 2025[61] Costs and Expenses - Operating income for Q2 2025 decreased by 25.5% to $546 million from $734 million in Q2 2024[28] - Total operating costs and expenses for Q2 2025 were $4,725 million, an increase of 9.6% from $4,311 million in Q2 2024[28] - Cash and equivalents as of March 31, 2025, were $667 million, down from $1,717 million as of September 30, 2024[30] - The company reported a net cash provided by continuing operating activities of $857 million for the first six months of 2025[31] - Total assets decreased to $54,467 million as of March 31, 2025, from $57,286 million as of September 30, 2024[30] Strategic Initiatives - The company plans to invest $2.5 billion in U.S. manufacturing capacity over the next 5 years to enhance its position in the medical device market[5] - The Advanced Patient Monitoring business unit launched the HemoSphere Alta™ Advanced Monitoring Platform, featuring AI-driven clinical decision support[5] - The company split its Integrated Diagnostic Solutions unit into two separate units to better align resources with business needs[33] - The company restructured its Life Sciences segment by splitting the Integrated Diagnostic Solutions unit into two distinct units to better align resources[48] Regulatory and Compliance Issues - The company received FDA clearance for the Phasix™ ST Umbilical Hernia Patch, marking a significant advancement in its product offerings[9] - BD was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% overall[9] - European regulatory initiative-related costs reached $104 million pre-tax, reflecting compliance efforts with new regulations[62] - The tax impact of specified items and other tax-related adjustments was ($297) million, influencing net earnings[61] - The company recorded $67 million in accruals impacting revenues due to legal matters and $175 million related to an SEC investigation[62] - Future costs for product remediation efforts included charges of $38 million to cost of products sold, indicating ongoing operational challenges[62] Challenges - The company faced significant challenges including macroeconomic conditions, supply chain disruptions, and competitive pressures impacting future performance[27] - Purchase accounting adjustments amounted to $1.503 billion pre-tax, impacting reported earnings significantly[61] - Integration costs incurred were $23 million pre-tax, while restructuring costs totaled $387 million pre-tax[61] - Transaction costs related to the Advanced Patient Monitoring acquisition were $48 million pre-tax, with financing costs recorded as ($8) million pre-tax[61] - Product, litigation, and other items accounted for $346 million pre-tax, affecting overall financial performance[62]

Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025."Amid a difficult operating environment impa ...

FRANKLIN LAKES, N.J., April 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 13, 2025 at 1:00 pm Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the l ...

Industry Overview - The Medical sector is experiencing a continued recovery in sales, with earnings increasing year over year by 4.7% on 9.4% higher revenues, although inflationary pressures and supply chain challenges persist [1][2] - The first-quarter earnings for the Medical sector are expected to improve by 35%, while sales are projected to increase by 7.8%, compared to the previous quarter's earnings growth of 13.4% and revenue growth of 9.4% [3] Medical Device Industry Insights - The medical device industry began 2025 with robust growth, driven by sustained demand for advanced healthcare solutions and the normalization of elective procedures, with the global market projected to reach $1.3 trillion by 2029 [4] - Challenges such as semiconductor shortages and workforce shortages in AI and robotics are impacting production and innovation [5] - Trade tensions, particularly U.S.-China tariffs, have increased operational costs for medical device manufacturers, with 75% of U.S.-marketed medical devices manufactured abroad [6] Company Performance Expectations - Becton Dickinson is expected to report strong second-quarter results, with a projected revenue growth of 16.3% year over year in its Medical division, although a slight dip of 1.3% is anticipated in the Life Sciences segment [8] - Cardinal Health is expected to show steady performance in its Pharmaceutical and Specialty Solutions segment, supported by strategic acquisitions, despite the impact of a key customer contract expiration [10] - Baxter International is projected to report moderate growth, with an estimated 6.6% sales growth in its Medical Products & Therapies segment, aided by operational recovery [11] - DexCom's outlook remains promising, with a full-year revenue guidance of $4.6 billion, driven by expanded U.S. prescriber coverage and strong international performance [12] - Stryker Corporation is expected to show strong growth across multiple segments, with projected U.S. and international sales reaching $4.74 billion and $1.59 billion, respectively [13]

Becton Dickinson and Company (BDX) , popularly known as BD, is scheduled to report second-quarter fiscal 2025 results on May 1, before market open.In the last reported quarter, the company’s earnings per share (EPS) of $3.43 surpassed the Zacks Consensus Estimate by 15.1%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 7.3%, on average. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s che ...

Analysts on Wall Street project that Becton Dickinson (BDX) will announce quarterly earnings of $3.28 per share in its forthcoming report, representing an increase of 3.5% year over year. Revenues are projected to reach $5.37 billion, increasing 6.4% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this ...